Patents by Inventor Robin Shattock
Robin Shattock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12661394Abstract: The invention relates to vaccines, and in particular, to vaccines for preventing, treating or ameliorating coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS), SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS). The invention is especially concerned with self-amplifying RNA replicons and genetic constructs or vectors encoding such RNA replicons, and their use in vaccine delivery for preventing infections of coronavirus. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: GrantFiled: March 26, 2021Date of Patent: June 23, 2026Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Robin Shattock, Paul McKay, Anna Blakney
-
Publication number: 20260115317Abstract: The present invention relates to gene therapy agents for the treatment of pulmonary alveolar proteinosis (PAP), particularly autoimmune PAP (aPAP). In particular, the present invention relates to gene therapy vectors which drive transient and/or low-level expression of granulocyte-macrophage colony-stimulating factor (GM-CSF), which provide a therapeutic effect without therapy-associated toxicity. The invention further relates to related products and an animal model of aPAP.Type: ApplicationFiled: October 2, 2023Publication date: April 30, 2026Inventors: Uta GRIESENBACH, Eric ALTON, Claudia Ivette JUAREZ-MOLINA, Helena LUND-PALAU, Robyn BELL, Cliff MORGAN, Robin SHATTOCK
-
Patent number: 12569548Abstract: The invention relates to RNA constructs encoding (i) at least one therapeutic biomolecule; and (ii) at least one innate inhibitor protein (IIP). The constructs are RNA replicons and saRNA molecules, and the invention includes genetic constructs or vectors encoding such RNA replicons. The invention extends to the use of such RNA constructs and replicons in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: GrantFiled: June 18, 2020Date of Patent: March 10, 2026Assignee: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Robin Shattock, Anna Blakney, Paul McKay
-
Publication number: 20260055165Abstract: The invention relates to monoclonal antibody production and isolation, and particularly, although not exclusively, to a novel feeder cell line for culturing a monoclonal antibody-producing B cell. The invention also extends to the use of the feeder cell line in culturing a monoclonal antibody-producing B cell, and isolating the B cell from the cell culture media. The invention further extends to methods for culturing and isolating a monoclonal antibody-producing B cell, as well as a method for isolating a monoclonal antibody.Type: ApplicationFiled: August 10, 2023Publication date: February 26, 2026Applicant: Imperial College Innovations LimitedInventors: Konstantinos PASCHOS, Robin SHATTOCK
-
Publication number: 20260034202Abstract: The disclosure provides a sub-micron particle comprising a first payload molecule, a lipid structure and a plurality of amphiphilic polymer chains surrounding the lipid structure. The first payload molecule is a macromolecule, optionally a nucleic acid. Additionally, the hydrophobicity of the amphiphilic polymer chains changes in response to an external stimulus.Type: ApplicationFiled: November 10, 2022Publication date: February 5, 2026Inventors: Rongjun Chen, Apanpreet K. Bhamra, Robin Shattock, Anna Blakney
-
Publication number: 20250051798Abstract: The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: ApplicationFiled: December 16, 2022Publication date: February 13, 2025Applicants: Imperial College Innovations Limited, VaxEquity LtdInventors: Paul McKay, Robin Shattock
-
Publication number: 20240315981Abstract: The invention relates to a sub-micron particle comprising a payload molecule and a lipid structure being surrounded by an outer layer comprising an amphiphilic copolymer. The invention extends to method of producing the sub-micron particle. The invention also encompasses pharmaceutical compositions and vaccines comprising the sub-micron particle and medical uses thereof.Type: ApplicationFiled: June 14, 2022Publication date: September 26, 2024Inventors: Rongjun Chen, Xuhan Liu, Robin Shattock, Anna Blakney, Yifan Liu
-
Publication number: 20240124530Abstract: The present invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: ApplicationFiled: December 17, 2021Publication date: April 18, 2024Applicants: Imperial College Innovations Limited, VaxEquity LtdInventors: Robin Shattock, Paul McKay, Michael Watson, Elaine Harper
-
Publication number: 20240101821Abstract: The invention relates to polymeric compositions, nanoparticles and vaccines comprising polymeric compositions. The invention extends to medical uses of the polymeric compositions, nanoparticles and vaccines. The invention further extends to methods of producing the polymeric compositions and nanoparticles.Type: ApplicationFiled: October 9, 2020Publication date: March 28, 2024Applicant: Imperial College Innovations LimitedInventors: Robin Shattock, Molly Stevens, Yunqing Zhu, Anna Blakney
-
Publication number: 20230364226Abstract: The invention relates to RNA constructs, and particularly, although not exclusively, to mRNA constructs and saRNA replicons and to nucleic acids and expression vectors encoding such RNA constructs. The invention extends to the use of such RNA constructs in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: ApplicationFiled: December 17, 2021Publication date: November 16, 2023Applicants: Imperial College Innovations Limited, VaxEquity LtdInventors: Robin Shattock, Paul McKay, Michael Watson, Elaine Harper
-
Publication number: 20230270841Abstract: The invention relates to vaccines, and in particular, to vaccines for preventing, treating or ameliorating coronavirus infections, such as severe acute respiratory syndrome coronavirus (SARS), SARS-CoV-2 and Middle East respiratory syndrome-related coronavirus (MERS). The invention is especially concerned with self-amplifying RNA replicons and genetic constructs or vectors encoding such RNA replicons, and their use in vaccine delivery for preventing infections of coronavirus. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: ApplicationFiled: March 26, 2021Publication date: August 31, 2023Applicant: Imperial College Innovations LimitedInventors: Robin Shattock, Paul McKay, Anna Blakney
-
Publication number: 20220265807Abstract: The invention relates to RNA constructs encoding (i) at least one therapeutic biomolecule; and (ii) at least one innate inhibitor protein (IIP). The constructs are RNA replicons and saRNA molecules, and the invention includes genetic constructs or vectors encoding such RNA replicons. The invention extends to the use of such RNA constructs and replicons in therapy, for example in treating diseases and/or in vaccine delivery. The invention extends to pharmaceutical compositions comprising such RNA constructs, and methods and uses thereof.Type: ApplicationFiled: June 18, 2020Publication date: August 25, 2022Applicant: IMPERIAL COLLEGE INNOVATIONS LIMITEDInventors: Robin Shattock, Anna Blakney, Paul McKay
-
Publication number: 20210386850Abstract: The invention relates to fusion proteins, and to the use of fusion proteins (or genetic constructs or vectors encoding such fusion proteins) to vaccinate against viral infections. The invention extends to pharmaceutical compositions comprising such fusion proteins or constructs for preventing and treating viral infections, and to methods and uses thereof.Type: ApplicationFiled: October 16, 2019Publication date: December 16, 2021Inventors: Robin Shattock, Yoann Aldon, Paul McKay